CathWorks at EuroPCR 2025
CathWorks, a frontline innovator in the realm of digital health, is set to make impactful contributions to the upcoming EuroPCR 2025 conference scheduled from May 20 to 23 at the Palais des Congrès in Paris, France. This conference serves as a platform for medical professionals and experts in cardiology to engage in discussions, presentations, and workshops focusing on cutting-edge advancements in the field.
Key Presentation Highlights
One of the pivotal moments at EuroPCR will be on Thursday when Dr. Toru Tanigaki of Gifu Heart Center, Japan, presents the one-year outcomes from the PROVISION1 Study. This landmark study marks Japan’s first prospective randomized controlled trial (RCT) that compares clinical outcomes between two methodologies: the FFRangio guidance versus invasive FFR guidance. Notably, the PROVISION study demonstrated significant advantages in terms of both economics and resource utilization for the non-invasive FFRangio technology compared to traditional methods. This session signifies not just a milestone for CathWorks but also underscores the growing interest in non-invasive cardiovascular diagnostics.
Educational Symposium
In conjunction with these presentations, CathWorks will host a lunchtime symposium entitled "The New Global Era of Patient Care with CathWorks FFRangio". This symposium will showcase experts including Dr. Rasha Al-Lamee from Imperial College London and Professor Ran Kornowski from Rabin Medical Center in Israel, discussing the transition and integration of the FFRangio System into routine clinical practice across various institutions. Prominent faculty such as Dr. Benjamin Honton, Dr. Thomas Keeble, Dr. Stephane Fournier, and Professor Hitoshi Matsuo will participate, providing insights into their experiences with the FFRangio system.
The symposium aims to facilitate knowledge exchange regarding the adoption of innovative technologies in cardiac care, aiming for improved patient outcomes.
Hands-on Demonstrations
The FFRangio System will also be available for hands-on demonstrations during the "Meet the Expert" sessions at the Medtronic booth. These sessions offer an invaluable opportunity for physicians to engage directly with leading experts, enhancing their understanding of the technology and its application in clinical settings. This hands-on experience is critical for exposing practitioners to the practical aspects of the FFRangio System, reinforcing CathWorks' commitment to education and innovative practice.
Strategic Partnership with Medtronic
Ramin Mousavi, President and CEO of CathWorks, expressed enthusiasm about the strategic partnership with Medtronic. He noted that this collaboration has significantly accelerated the adoption and seamless integration of the FFRangio system throughout various catheterization labs worldwide. Mousavi stated, "We are excited about the prominent presence of FFRangio at EuroPCR and look forward to continuing to partner with the interventional cardiology community to make FFRangio the standard of care globally."
About CathWorks
CathWorks is a pioneer in digital health innovations, revolutionizing the diagnosis and treatment landscape for cardiovascular diseases. The FFRangio® System leverages artificial intelligence combined with advanced computational techniques, transforming traditional methods by extracting physiological information from standard angiograms and eliminating the necessity for invasive pressure wires. This innovative approach enables medical professionals to obtain prompt and reliable FFR values across the coronary tree, potentially leading to enhanced patient management and outcomes.
With such significant advancements showcased at EuroPCR 2025, CathWorks continues to position itself at the forefront of cardiovascular health technology, remaining committed to improving patient care through innovative solutions. To stay updated, visit
CathWorks' website and follow them on LinkedIn.